- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate ; day:19 ; month:9 ; year:2018 ; pages:1-4
Drugs in R & D ; (19.9.2018), 1-4
- Creator
-
Lashari, Bilal H.
- Contributor
-
Vallatharasu, Yazhini
Kolandra, Lakshmi
Hamid, Mohsin
Uprety, Dipesh
SpringerLink (Online service)
- DOI
-
10.1007/s40268-018-0247-7
- URN
-
urn:nbn:de:101:1-2018110921142691298514
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lashari, Bilal H.
- Vallatharasu, Yazhini
- Kolandra, Lakshmi
- Hamid, Mohsin
- Uprety, Dipesh
- SpringerLink (Online service)
Other Objects (12)
The First FDA-Approved Antibody-Drug Conjugate
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting
A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
A Potential Antibody–Drug Conjugate Targeting Human LIV1 for the Treatment of Triple-Negative Breast Cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
The First FDA-Approved Antibody-Drug Conjugate
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting
A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
A Potential Antibody–Drug Conjugate Targeting Human LIV1 for the Treatment of Triple-Negative Breast Cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
The First FDA-Approved Antibody-Drug Conjugate
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting
A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
A Potential Antibody–Drug Conjugate Targeting Human LIV1 for the Treatment of Triple-Negative Breast Cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein